DOI QR코드

DOI QR Code

Molecular Involvement and Prognostic Importance of Fms-like Tyrosine Kinase 3 in Acute Myeloid Leukemia

  • Shahab, Sadaf (National Institute of Blood Diseases and Bone Marrow Transplantation) ;
  • Shamsi, Tahir S. (National Institute of Blood Diseases and Bone Marrow Transplantation) ;
  • Ahmed, Nuzhat (National Institute of Blood Diseases and Bone Marrow Transplantation)
  • Published : 2012.09.30

Abstract

AML (Acute myeloid leukemia) is a form of blood cancer where growth of myeloid cells occurs in the bone marrow. The prognosis is poor in general for many reasons. One is the presence of leukaemia-specific recognition markers such as FLT3 (fms-like tyrosine kinase 3). Another name of FLT3 is stem cell tyrosine kinase-1 (STK1), which is known to take part in proliferation, differentiation and apoptosis of hematopoietic cells, usually being present on haemopoietic progenitor cells in the bone marrow. FLT3 act as an independent prognostic factor for AML. Although a vast literature is available about the association of FLT3 with AML there still is a need of a brief up to date overview which draw a clear picture about this association and their effect on overall survival.

References

  1. Abu-Duhier FM, Goodeve AC, Wilson GA, et al (2001). Genomic structure of human FLT3: implications for mutational analysis. Br J Haematol, 113, 1076-7.
  2. Abu-Duhier FM, Goodeve AC, Wilson GA, et al (2001). Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol, 113, 983-8. https://doi.org/10.1046/j.1365-2141.2001.02850.x
  3. Arrigoni P, Beretta C, Silvestri D, et al (2003). FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. Br J Haematol, 120, 89-92. https://doi.org/10.1046/j.1365-2141.2003.04032.x
  4. Birg F, Rosnet O, Carbuccia N, Birnbaum D (1994). The expression of FMS, KITand FLT3 in hematopoietic malignancies. Leuk. Lymphoma, 13, 223-7. https://doi.org/10.3109/10428199409056285
  5. Bloomfield CD, Goldman A, Hassfeld D, DelaChapelle A (1984). Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet, 11, 332-0. https://doi.org/10.1016/S0165-4608(84)80022-9
  6. David G, Robert KH (2009). Independent prognostic factors for AML outcome hematology. Blood, 385-5.
  7. David G, Robert KH, Anthony VM (2010). Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354-5. https://doi.org/10.1182/blood-2009-11-254441
  8. Deguchi K, Gilliland DG (2002). Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML Leukemia. ?, 16, 740-4. https://doi.org/10.1038/sj.leu.2402500
  9. Dohner K, Dohner H (2008). Molecular characterization of acute myeloid leukemia. Haematologica, 93, 976-82. https://doi.org/10.3324/haematol.13345
  10. Elias C, Steven HS, Nancy LH, et al (2011). The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, ?, 1-9.
  11. Farhad Z, Mohammad M, Mohammad M (2010). Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes. Arch Iran Med, 13, 21-5.
  12. Frascella F (2006). FLT3-ITD: technical approach and characterization of cases with double duplications. Gene Therapy & Mol Biol, 10, 165-2.
  13. Frohling S, Schlenk RF, Breitruck J, et al (2002). Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics:a study of the AML Study Group Ulm. Blood, 100, 4372-0. https://doi.org/10.1182/blood-2002-05-1440
  14. Gale ER (2003). FLT3 mutations and leukaemia. Br J Haematol, 122, 523-38. https://doi.org/10.1046/j.1365-2141.2003.04500.x
  15. Gaymes TJ, Mufti GJ, Rassool FV, et al (2002). Myeloid leukemias have increased activity of the nonhomologous end joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res, 62, 2791-7.
  16. Govedarovic N, Marjanovic G (2011). Frequency and prognostic impact of FLT3/ITD mutation in patients with acute myeloid leukaemia. J BUON, 16, 108-11.
  17. Gu T-l, Nardone J, Wang Y, et al (2011). Survey of activated FLT3 signaling in leukemia. PLoS ONE, 6, ?-?. https://doi.org/10.1371/journal.pone.0019169
  18. Horiike S, Yokota S, Nakao M, et al (1997). Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia Leukemia. ?, 11, 1442-6. https://doi.org/10.1038/sj.leu.2400770
  19. Ishii E, Zaitsu M, IharaK, HaraT, MiyazakiS (1999). High expression but no internal tandem duplication of FLT3 in normal hematopoietic cells. Ped. Hematol Oncol, 16, 437-1. Islam A (1992). The origin and spread of human leukemia. Med Hypotheses, 39, 110-8.
  20. Iwai T, Yokota S, Nakao M (1999). Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. Leukemia, 13, 38-43, https://doi.org/10.1038/sj.leu.2401241
  21. James MF (2010). New prognostic markers in acute myeloid leukemia:perspective from the clinic. Hematology, ?, 47-55 https://doi.org/10.1182/asheducation-2010.1.47
  22. Jilani I, Estey E, Manshuri T, et al (2003). Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia, 17, 114-9. https://doi.org/10.1038/sj.leu.2402743
  23. Kainz B, Heintel D, Marculescu R, et al (2002). Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). J Hematol, 3, 283-9. https://doi.org/10.1038/sj.thj.6200196
  24. Katharina W, Frederik D, Felicitas T, et al (2011). FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica, 96, 681-6. https://doi.org/10.3324/haematol.2010.034074
  25. Kiyoi H, Ohno R, Ueda R, et al (2002). Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene, 21, 2555-3. https://doi.org/10.1038/sj.onc.1205332
  26. Kondo M, Horibe K, Takahashi Y, et al (1999). Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Ped Oncology, 33, 525-9. https://doi.org/10.1002/(SICI)1096-911X(199912)33:6<525::AID-MPO1>3.0.CO;2-8
  27. Kottaridis PD, Gale RE, Frew ME, et al (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood. ?, 98, 1752-9. https://doi.org/10.1182/blood.V98.6.1752
  28. Li Z, Amit V (2009). Targeting Signal Transduction Pathways in Hematopoietic Disorders. 2009.Mol. basis of hematopoiesis A Wickrema and Bke(ed)Springer.231_252. https://doi.org/10.1002/cncr.10598
  29. Liang DC, Shih LY, Hung IJ, et al (2002). Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Cancer , 94, 3292-8. https://doi.org/10.1002/cncr.10598
  30. Libura M, Asnafi V, Tu A, et al (2002). Flt3 and MLL internal tandem duplications and topoisomerase II breakages reflect a common category of genotoxic stress: an EORTC study. Blood, 100, 530.
  31. Maroc N, Rottapel R, Rosnet O, et al (1993). Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene, 8, 909-8. https://doi.org/10.1182/blood.V97.1.89
  32. Meshinchi S, Woods WG, Stirewalt DL, et al (2001). Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood, 97, 89-94. https://doi.org/10.1182/blood.V97.1.89
  33. Moreno I, Guillermo M, Pascual B (2003). Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica, 88, ?-?. https://doi.org/10.1016/S1525-1578(10)60458-8
  34. Murphy KM, Kathleen MM, Mark L, et al (2003). Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay j mol diagn. ?, 5, 96-102. https://doi.org/10.1016/S1525-1578(10)60458-8
  35. Nakao M, Yokota S, Iwai T, et al (1996). Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 1911-8. https://doi.org/10.1007/s00277-007-0325-3
  36. Natasa C, Natasa T, Sanja A, et al (2007). Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia. Annal Hematol, 86, 741-7. https://doi.org/10.1007/s00277-007-0325-3
  37. Nicolas B, Aline R, Valeria B, et al (2005). Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood, 106, 3618-20. https://doi.org/10.1182/blood-2005-05-2174
  38. Noguera NI, Breccia M, Divona M, et al (2002). Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia, 16, 2185-9. https://doi.org/10.1038/sj.leu.2402723
  39. Palumbo GA, Tanteri V, Buglio D, et al (2002). FLT3-activating mutations in acute promyelocytic leukemia: higher incidence of ITD in BCR3 patients. Blood, 100, 326. https://doi.org/10.1186/1471-2407-10-513
  40. Patrick C, Michelle K, Anny X, et al (2010). FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia. BMC Cancer, 10, 513. https://doi.org/10.1186/1471-2407-10-513
  41. Pradeep SC, Bharat B, Ashwani K, et al (2010). Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features. Med Oncol, 28, 544-51.
  42. Rabab A, Dina S, Emad A (2011). Prognostic significance of FLT3 internal tandem duplication in Egyptian acute myeloid leukemia and normal cytogenetics. Compar Clin Pathol, ?, 1-13. https://doi.org/10.1056/NEJMoa074306
  43. Richard FS, Konstanze D, Jürgen K (2008). For the German- Austrian acute myeloid leukemia study group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med, 358, 1909-8. https://doi.org/10.1056/NEJMoa074306
  44. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE (2000). Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia, 14, 675-3. https://doi.org/10.1038/sj.leu.2401731
  45. Rosemary EG, Claire G, Christopher A, et al (2008). The impact of FLT3 internal tandem duplication mutant level, number size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood, 111, 2776-4. https://doi.org/10.1182/blood-2007-08-109090
  46. Rosnet O, Schiff C, Pebusque MJ, et al (1993). Human FLT3/ FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood, 82, 1110-9.
  47. Schneider F, Hoster E, Schneider S, et al (2011). Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol, 91, 9-18, https://doi.org/10.1182/blood.V100.1.59
  48. Zhong S, Hu P, Ye TZ, et al (1999). A role for PML and the nuclear body in genomic stability. Oncogene, 18, 7941-7.
  49. Schnittger S, Schoch C, Dugas M, et al (2002). Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59-6. https://doi.org/10.1182/blood.V100.1.59
  50. Schnittger S, Bacher U, Kern W, et al (2011). FLT3 mutations in acute promeylocytic leukemia: high association with type-S PML⁄ RARa isoform but without prognostic impact. Leukemia, 25, 1297-304. https://doi.org/10.1038/leu.2011.97
  51. ShihLY, Kuo MC, LiangDC (2002 ). FLT3 mutations in acute promeylocytic leukemia: high association with type-S PML⁄ RARa isoform but without prognostic impact. Blood, 100, 326. https://doi.org/10.1186/1756-8722-4-13
  52. Shinichiro T (2011). Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol, 4, 13. https://doi.org/10.1186/1756-8722-4-13
  53. Shurin MR, Esche C, Lotze MT (1998). FLT3: receptor and ligand. Biology and potential clinical application. ?, 9, 37-48. https://doi.org/10.1016/S1359-6101(97)00035-X
  54. Spiekermann K, Bagrintseva K, Schoch C, et al (2002). A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood, 100, 3423-5. https://doi.org/10.1182/blood-2002-03-0953
  55. Stirewalt DL, Radich JP (2003). The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer, 3, 650-65. https://doi.org/10.1038/nrc1169
  56. Stirewalt DL, Kopecky KJ, Meshinchi S, et al (2001). FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood, 97, 3589-95 https://doi.org/10.1182/blood.V97.11.3589
  57. Tara KG, David W, Yichu C, Johanna MV, Yin X, (2009). Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. Oncol, 2, 23. https://doi.org/10.1182/blood.V99.12.4326
  58. Thiede C, Steudel C, Mohr B, et al (2002). Analysis of FLT3- activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-5. https://doi.org/10.1182/blood.V99.12.4326
  59. WangL, Wei-lai X, Hai-tao M, et al (2010). FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics. J Zhejiang Uni, 11, ?-?. https://doi.org/10.1038/sj.leu.2403917
  60. Warner JK, Wang JCY, Takenaka K, et al (2005). Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia, 19, 1794-5. https://doi.org/10.1038/sj.leu.2403917
  61. Whitman SP, Archer KJ, Feng L, et al (2001). Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res, 61, 7233-9. https://doi.org/10.1038/sj.leu.2401760
  62. Xu F, Taki T, Eguchi M, et al (2000). Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group (letter). Leukemia, 14, 945-7. https://doi.org/10.1038/sj.leu.2401760
  63. Xu F, Taki T, Yang HW, et al (1999). Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Bri J Haematol, 105, 155-62. https://doi.org/10.1111/j.1365-2141.1999.01284.x
  64. YamamotoY, Kiyoi H, Nakano Y, et al. (2001). Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 97, 2434-9. https://doi.org/10.1182/blood.V97.8.2434
  65. Yeo-Kyeoung K, Hee-Nam K, Se Ryeon L, (2010). Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol, 45, 36-5. https://doi.org/10.5045/kjh.2010.45.1.36
  66. YokotaS, Kiyoi H, Nakao M, et al (1997). Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia, 11, 1605-9. https://doi.org/10.1038/sj.leu.2400812
  67. Zwaan CM, Meshinchi S, Radich JP, et al (2002). Flt3 internal tandem duplication in childhood acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood, 100, 33.
  68. Islam A (1992). The origin and spread of human leukemia. Med Hypotheses, 39, 110-8. https://doi.org/10.1016/0306-9877(92)90149-7

Cited by

  1. Survival Outcome of AML Patients with and without TKD Mutations vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10995
  2. Overall Survival in Acute Myeloid Leukaemia Patients with and without Internal Tandem Duplication vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.393